Home/ Stocks/ CGTX

Cognition Therapeutics, Inc. Common Stock

CGTX XNAS

$1.10 -0.01 (-0.88%) ▼ 15-min delayed

Open

$1.13

High

$1.14

Low

$1.07

Volume

499.0K

Market Cap

$99.75M

About Cognition Therapeutics, Inc. Common Stock

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 25 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-4,930,000	$-0.06
Q2 2025	$0	$-6,734,000	$-0.11
Q1 2025	$0	$-8,480,000	$-0.14
FY 2024	$0	$-33,971,000	$-0.86

Related Market News

No specific coverage for CGTX yet. Check out our latest market news or earnings calendar.

Get CGTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cognition Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.